Buy : Suven Life Science
CMP : 33
Target : 42
Upside : 30%
Time Frame : 3 months
Chart View ( Click the picture to view enlarged )
Recent Positive News from Suven Life Sciences
Suven Life Sciences secures Two Product Patents in all Russian countries (Eurasia Region)
Suven Life Sciences Ltd on March 24, 2008 has announced that two product patents were granted in Eurasia (009193 and 009367) for two of their New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid until 2023. The patents are valid in all contracting countries like Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Moldova, Russia, Tajikistan and Turkmenistan.
These granted patents are exclusive intellectual property of Suven and are achieved through the exclusive internal discovery research efforts. Products out of these inventories which are in pre-clinical development may be out-licensed at the stage of clinical Phase-I or Phase-II stage.
We are very pleased by the issuance of these patents to Suven for our drug candidates that are being developed for CNS disorders which targets an $ 18 billion potential market opportunity globally says Venkat Jasti, CEO of Suven.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-degenarative disorders like Attention deficient hyperactivity, Alzheimer's, Parkinson, Schizophrenia and Huntington's.
Suven Life Science is a biopharmaceutical Company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidated currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity in addition to developmental candidates in Alzheimer's disease and Schizophrenia.
|Suven Life Establishes Second CNS Drug Discovery Collaboration with Lilly|
|March 12, 2008|
Suven Life Sciences Ltd, on March 12, 2008 has announced that the Company has signed a second agreement with Eli Lilly and company, a US based global pharmaceutical company to collaborate on the pre-clinical research of molecules in the therapeutic area of central nervous system disorders (CNS).
As per the collaboration agreement, Suven will be responsible for discovery activities related to the identification and selection of clinical candidates in the area of CNS, in close association with Lilly.
Under the terms of the collaboration agreement, Suven will receive research funding and as well as potential discovery and development milestone payments in the range of $ 19 million to $ 23 million per candidate and potential royalties on net sales of any products that may be successfully commercialized from the collaboration.
We are very pleased and excited that Lilly has continued collaborate with us in the CNS arena, thus showing the confidence in Suven's drug discovery capabilities. says Dr. Ramakrishna Nirogi, Vice President, Drug Discovery of Suven life Sciences.
We believe our collaborations with Lilly validate Suven's leadership position in CNS drug discovery says Venkat Jasti, CEO of Suven Life Sciences. This Collaboration leverages Suven's small molecule drug discovery expertise with Lilly'S expertise and leadership position in CNS, with the goal of creating innovative products for unmet medical needs.